At rennesens GmbH the enormous potential of biotechnology is used to achieve significant improvements in medical diagnostics.
In co-operation with other biotechnological companies in Germany rennesens GmbH develops new test methods, based on molecular and nanotechnological processes.
With CardioDetect rennesens GmbH offered worldwide the first rapid test card that detects the new cardiac marker
h-FABP, facilitating a much earlier diagnosis and appropriate treatments of patients with acute myocardial infarction. |
lab h-FABP
